Skip to content Skip to footer
Subscribe Now
Viewpoints_Dr. Saoirse O'Sullivan
VIEWPOINTS

PharmaShots Interview: Artelo Bio’s Dr. Saoirse O’Sullivan Shares Insights on Synthetic Cannabinoid for Cancer Anorexia

In an interview with PharmaShots, Dr. Saoirse O'Sullivan, Ph.D., Scientific Advisor to Artelo Bio shares insights on new cannabinoids, their relevancy, and the other opportunities that can arise from modulating the ECS. Shots: The endocannabinoid system is a network of neurotransmitters and receptors throughout the body that can have a significant impact on improving human health when affected…
April 23, 2021

Read more

Viewpoints_Douglas E. Williams
VIEWPOINTS

PharmaShots Interview: Codiak BioSciences’ Douglas E. Williams Shares Insight on the Potential of its Engineered Exosomes

In an interview with PharmaShots, Douglas E. Williams, Ph.D., President and Chief Executive Officer of Codiak BioSciences shares insights on the potential of engineered exosomes and the data presented at SITC 2020. Shots: Codiak demonstrated the potential of engineered exosomes -  extracellular vesicles that act like the body's FedEx delivery trucks to carry messengers between cells -…
April 20, 2021

Read more

Viewpoints_Dr. Kimberly Smith
VIEWPOINTS

PharmaShots Interview: ViiV Healthcare’s Dr. Kimberly Smith Shares Insight on the Data Presented at CROI 2021

In an interview with PharmaShots, Dr. Kimberly Smith, Head of Global Research and Medical Strategy at ViiV Healthcare shares insights on the clinical data of GSK3640254 (GSK'254) at CROI 2021. She also highlights the key points of P-IIIb ATLAS-2M study that provide further evidence for both the once-monthly and every 2-months dosing regimens of long-acting cabotegravir and…
April 19, 2021

Read more

Viewpoints_Douglas Onsi
VIEWPOINTS

PharmaShots Interview: Leap Therapeutic’s Douglas Onsi Shares Insight on its Lead Candidate, DKN-01

In an interview with PharmaShots, Douglas Onsi, CEO and President of Leap Therapeutics shares insights on the clinical data of DKN-01 along with its mechanism. He also highlights the company's growth, plans, goal etc. Shots: DKK1 is a secreted protein that modulates cell signaling pathways known as the Wnt signaling pathways, as well as the PI3 kinase…
April 14, 2021

Read more

Viewpoints_Tej Patel
VIEWPOINTS

PharmaShots Interview: Fluxergy’s Tej Patel Shares Insight on Multimodal Diagnostic System

In an interview with PharmaShots, Tej Patel, CEO of Fluxergy shared his views on Fluxergy's CE Marking and how it will democratize healthcare while creating better clinical outcomes. Shots: Fluxergy's One-hour COVID-19 test requires less than 2-3 minutes of hands-on time and provides lab-quality RT-PCR test results within an hour. The Fluxergy analyzer is a compact, high-density…
April 13, 2021

Read more

Viewpoints_Dr. Gail McIntyre
VIEWPOINTS

PharmaShots Interview: Aravive’ s Dr. Gail McIntyre Shares Insight on AVB-500 and its Potential Against ccRCC

In an interview with PharmaShots, Dr. Gail McIntyre, CEO of Aravive shared her views on the AVB-500, its potential against ccRCC, and the design of the clinical trial evaluating the therapy. He also shed light on epidemiology of Clear Cell Renal Cell Carcinoma. Shots: AVB-500 is being evaluated in ccRCC, has been tested in preclinical models of…
April 9, 2021

Read more

Viewpoints_Marc Meachem
VIEWPOINTS

PharmaShots Interview: Marc Meachem Shares Insight on the ViiV’s 2021 Commitment to the Community

In an interview with PharmaShots, Marc Meachem, Head of US External Affairs at ViiV Healthcare shared his views on the company's approach towards the community. He also shed light on the grants and funding received for the betterment of HIV patients. Shots: ViiV Healthcare is doubling its community investments in 2021 with the goal of disrupting the enduring…
April 7, 2021

Read more

Viewpoints_Dietrich Stephan
VIEWPOINTS

PharmaShots Interview: NeuBase Therapeutics’ Dietrich Stephan Shares Insight on its Approach to Genetic Medicine

In an interview with PharmaShots, Dietrich Stephan, Ph.D., CEO of NeuBase Therapeutics shared his views on the importance of preclinical in vivo data for PATrOL-enabled anti-gene for myotonic dystrophy type 1. Shots: NeuBase announced in vitro and in vivo data for its DM1 program, demonstrating the potential of its genetic medicine platform to target the disease-causing…
April 6, 2021

Read more

Viewpoints_Marie Schiller
VIEWPOINTS

PharmaShots Interview: Eli Lilly’s Marie Schiller Shares Insight on the Collaboration with Welldoc on New Version of BlueStar App

In an interview with PharmaShots, Marie Schiller Vice President of Product Development for Connected Care and Insulins at Lilly shared her views on its collaboration with Welldoc to integrate Welldoc's insulin management technology into Lilly's connected insulin solutions. Shots: Lilly and Welldoc are teaming up to create a new version of Welldoc's BlueStar app which will be integrated…
April 5, 2021

Read more

Load more